Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ductal Adenocarcinoma of the Pancreas”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT06981806
What this trial is testing

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Who this might be right for
Metastatic Pancreatic Ductal Adenocarcinoma
Arsen Osipov 24
Testing effectiveness (Phase 2)Ended earlyNCT02732938
What this trial is testing

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

Who this might be right for
Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer 22
Early research (Phase 1)Study completedNCT05440942
What this trial is testing

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Peter Hosein, MD 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT04753879
What this trial is testing

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Who this might be right for
Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Early research (Phase 1)Ended earlyNCT02782182
What this trial is testing

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
University of Chicago 1
Testing effectiveness (Phase 2)Study completedNCT02042378
What this trial is testing

Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Who this might be right for
Pancreatic CancerPancreatic Ductal Adenocarcinoma
pharmaand GmbH 19
Not applicableActive Not RecruitingNCT03583528
What this trial is testing

DOTATOC PET/CT for Imaging NET Patients

Who this might be right for
Neuroendocrine TumorsInsulinomaGastrinoma+13 more
British Columbia Cancer Agency 800
Not applicableStudy completedNCT06980792
What this trial is testing

Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases

Who this might be right for
Pancreas NeoplasmsLiver MetastasisPancreas Ductal Adenocarcinoma+3 more
Azienda Ospedaliero-Universitaria di Modena 90
Not applicableStudy completedNCT03257150
What this trial is testing

The Use of Irreversible Electroporation in Pancreatic Ductal Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma
University Health Network, Toronto 12
Not applicableNot Yet RecruitingNCT05611359
What this trial is testing

Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 60
Not applicableTemporarily pausedNCT03444948
What this trial is testing

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Centre hospitalier de l'Université de Montréal (CHUM) 108
Testing effectiveness (Phase 2)Study completedNCT04704154
What this trial is testing

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Who this might be right for
Solid Tumors
Bayer 175
Testing effectiveness (Phase 2)Study completedNCT05031494
What this trial is testing

Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Who this might be right for
MelanomaPancreatic Ductal Adenocarcinoma
Eucure (Beijing) Biopharma Co., Ltd 40
Not applicableUnknownNCT04115527
What this trial is testing

Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Ruijin Hospital 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07745790
What this trial is testing

Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Ductal AdenocarcinomaLiver NeoplasmsLung Neoplasms
Ruijin Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05968326
What this trial is testing

The Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Who this might be right for
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc. 260
Testing effectiveness (Phase 2)Study completedNCT03496662
What this trial is testing

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine 40
Testing effectiveness (Phase 2)Study completedNCT05641896
What this trial is testing

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Who this might be right for
Gastrointestinal CancersCholangiocarcinomaGastric Cancer+3 more
SOFIE 109
Testing effectiveness (Phase 2)Looking for participantsNCT05688215
What this trial is testing

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Who this might be right for
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center 56
Early research (Phase 1)Looking for participantsNCT05013216
What this trial is testing

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Who this might be right for
High Risk CancerPancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 37
Next Page